innjoInnovaInnova2500-2937КГМУ10.21626/innova/2024.1/12innjo-561Research ArticleСтатьиВозможности прогнозирования преэклампсии на современном уровне (обзор литературы)The possibilities of predicting of the preeclampsia on the modern level (literature review)ПахомовСергей ПетровичPakhomovSergey Petrovich

Доктор медицинских наук

Doctor of Medical Sciences

pakhomovsp@kursksmu.netГоловченкоОлег ВасильевичGolovchenkoOleg Vasilyevich

Кандидат медицинских наук

Candidate of Medical Sciences

Курский государственный медицинский университетРоссияKursk State Medical UniversityRussian FederationГруппа клиник «Промедика»РоссияPromedika Group of clinicsRussian Federation2024240420241014046Copyright © Пахомов С.П., Головченко О.В., 20242024Пахомов С.П., Головченко О.В.Pakhomov S.P., Golovchenko O.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.innova-journal.ru/jour/article/view/561

Преэклампсия является одной из ведущих причин материнской смертности. Поэтому вопросы ранней диагностики, а главное индивидуального прогнозирования являются на сегодняшний день одной из самых актуальных задач практического акушерства. За последние годы предпринято множество попыток создания способов персонализированного подхода к прогнозу преэклампсии. Но до сегодняшнего дня проблема остается не решенной. В настоящей обзорной статье представлены наиболее значимые методики индивидуального прогноза преэклампсии на доклиническом этапе на основе генетических, иммунологических и биохимических маркеров

The preeclampsia is one of the main causes of maternal mortality. For this reason the issues of early diagnosis, and most importantly individual prediction are currently one of the most urgent aim for practical obstetrics. To the last years many ways has been attempted to creating methods of a personalized approach to the prognosis of the preeclampsia. However, until this day, the problem remains unresolved. This review article presents the most significant methods of individual prognosis of preeclampsia at the preclinical stage based on genetic, immunological and biochemical markers.

осложнения беременностипреэклампсияперсонализированная медицинаиндивидуальное прогнозированиеpregnancy complicationspreeclampsiapersonalized medicineindividual prognosisReferencesБорис Д.А., Кан Н.Е., Тютюнник В.Л., Ховхаева П.А. Патогенетические аспекты преэклампсии. // Акушерство и Гинекология 2015 № 12 с. 11-15.Борис Д.А., Кан Н.Е., Тютюнник В.Л., Ховхаева П.А. Патогенетические аспекты преэклампсии. // Акушерство и Гинекология 2015 № 12 с. 11-15.Кан Н.Е., Беднягин Л.А., Долгушина Н.В., Тютюнник В.Л., Ховхаева П.А., Сергунина О.А., Тютюнник Н.В., Амирасланов Э.Ю. Клинико-анамнестические факторы риска развития преэклампсии у беременных. // Акушерство и Гинекология 2016 №6 с.39-44Кан Н.Е., Беднягин Л.А., Долгушина Н.В., Тютюнник В.Л., Ховхаева П.А., Сергунина О.А., Тютюнник Н.В., Амирасланов Э.Ю. Клинико-анамнестические факторы риска развития преэклампсии у беременных. // Акушерство и Гинекология 2016 №6 с.39-44Макаров О.В., Волкова Е.В., Джохадзе Л.С. Клинические аспекты преэклампсии // Российский вестник акушера-гинеколога - 2011, - № 4, - с. 29-35.Макаров О.В., Волкова Е.В., Джохадзе Л.С. Клинические аспекты преэклампсии // Российский вестник акушера-гинеколога - 2011, - № 4, - с. 29-35.Преэклампсия. Эклампсия. Отеки, протеинурия и гипертензивные расстройства во время беременности, в родах и послеродовом периоде. Клинические рекомендации. Москва. 2021 г.Преэклампсия. Эклампсия. Отеки, протеинурия и гипертензивные расстройства во время беременности, в родах и послеродовом периоде. Клинические рекомендации. Москва. 2021 г.Серов В.Н., Нестерова Л.А. Особенности современного акушерства. // Акушерство и Гинекология. 2022, -№ 3, -с. 5-11.Серов В.Н., Нестерова Л.А. Особенности современного акушерства. // Акушерство и Гинекология. 2022, -№ 3, -с. 5-11.Сидорова И.С., Никитина Н.А. Преэклампсия как гестационный иммунокомплексный комплементопосредованный эндотелиоз. //Российский вестник акушера-гинеколога. - 2019, Т. 19, - №1, -с. 5-11.Сидорова И.С., Никитина Н.А. Преэклампсия как гестационный иммунокомплексный комплементопосредованный эндотелиоз. //Российский вестник акушера-гинеколога. - 2019, Т. 19, - №1, -с. 5-11.Сухих Г.Т., Вихляева Е.М., Ванько Л.В. и др. Эндотелиальная дисфункция в генезе перинатальной патологии // Акуш. и гин. ‒ 2008. ‒ № 5. ‒ С. 3‒7.Сухих Г.Т., Вихляева Е.М., Ванько Л.В. и др. Эндотелиальная дисфункция в генезе перинатальной патологии // Акуш. и гин. ‒ 2008. ‒ № 5. ‒ С. 3‒7.Тимохина Е.В., Стрижаков А.Н., Белоцерковцева Л.Д., Федюнина И.А., Зинин В.Н., Песегова С.В. Новые маркеры раннего прогнозирования преэклампсии. // Акушерство и Гинекология. 2022, -№ 6, - с. 50-58Тимохина Е.В., Стрижаков А.Н., Белоцерковцева Л.Д., Федюнина И.А., Зинин В.Н., Песегова С.В. Новые маркеры раннего прогнозирования преэклампсии. // Акушерство и Гинекология. 2022, -№ 6, - с. 50-58Ходжаева З.С., Шмаков Р.Г., Коган Е.А.. Щеголев А.И., Клименченко Н.И., Акатьева А.С., Вавина О.В., Воднева Д.Н., Романова В.В., Сухих Г.Т. Клинико-анамнестические особенности, плацента и плацентарная площадка при ранней и поздней преэклампсии. Aкушерство и гинекология. 2015; 4: 25-31Ходжаева З.С., Шмаков Р.Г., Коган Е.А.. Щеголев А.И., Клименченко Н.И., Акатьева А.С., Вавина О.В., Воднева Д.Н., Романова В.В., Сухих Г.Т. Клинико-анамнестические особенности, плацента и плацентарная площадка при ранней и поздней преэклампсии. Aкушерство и гинекология. 2015; 4: 25-31Шелехин А.П., Баев О.Р., Красный А.М. Сравнение течения и исходов беременностей, осложненных гипертензивными расстройствами. //Акушерство и гинекология. 2023; 1: 41-47Шелехин А.П., Баев О.Р., Красный А.М. Сравнение течения и исходов беременностей, осложненных гипертензивными расстройствами. //Акушерство и гинекология. 2023; 1: 41-47Шифман Е.М. Преэклампсия, эклампсия, HELLP-синдром. – Петрозаводск: «ИнтелТек», 2003.Шифман Е.М. Преэклампсия, эклампсия, HELLP-синдром. – Петрозаводск: «ИнтелТек», 2003.Akolekar R., Minekawa R., Veduta A. et al. Maternal plasma inhibin A at 11-13 weeks of gestation in hypertensive disorders of pregnancy // Prenat. Diagn. – 2009. – Vol. 29, № 8. – P. 753‒760Akolekar R., Minekawa R., Veduta A. et al. Maternal plasma inhibin A at 11-13 weeks of gestation in hypertensive disorders of pregnancy // Prenat. Diagn. – 2009. – Vol. 29, № 8. – P. 753‒760Banzola I., Farina A., Concu M. et al. Performance of a panel of maternal serum markers in predicting preeclampsia at 11—15 weeks’ gestation. Prenat Diagn 2007; 27: 1005—1010.Banzola I., Farina A., Concu M. et al. Performance of a panel of maternal serum markers in predicting preeclampsia at 11—15 weeks’ gestation. Prenat Diagn 2007; 27: 1005—1010.Burton G.J., Jauniaux E. Oxidative stress. Best Pract. Res. Clin. Obstet. Gynaecol. 2011; 25(3): 287-99.Burton G.J., Jauniaux E. Oxidative stress. Best Pract. Res. Clin. Obstet. Gynaecol. 2011; 25(3): 287-99.Chafetz I., Kuhnreich I., Sammar M. et al. First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction // Am. J. Obstet. Gynecol. – 2007. – Vol. 197. – P. 35–37.Chafetz I., Kuhnreich I., Sammar M. et al. First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction // Am. J. Obstet. Gynecol. – 2007. – Vol. 197. – P. 35–37.Chavarria M.E., Lara-Gonzalez L., Garcia-Paleta Y. et al. Adhesion molecules changes at 20 gestation weeks in pregnancies complicated by preeclampsia. Eur J Obstet Gynecol Reprod Biol 2008; 137: 157—164Chavarria M.E., Lara-Gonzalez L., Garcia-Paleta Y. et al. Adhesion molecules changes at 20 gestation weeks in pregnancies complicated by preeclampsia. Eur J Obstet Gynecol Reprod Biol 2008; 137: 157—164Chavarría M.E., Lara-González L., González-Gleason A. et al. Prostacyclin/thromboxane early changes in pregnancies that are complicated by preeclampsia // Am. J. Obstet. Gynecol. – 2003. – Vol. 188, № 4. – P. 986‒992.Chavarría M.E., Lara-González L., González-Gleason A. et al. Prostacyclin/thromboxane early changes in pregnancies that are complicated by preeclampsia // Am. J. Obstet. Gynecol. – 2003. – Vol. 188, № 4. – P. 986‒992.Chien P.F., Arnott N., Gordon A. et al. How useful is uterine artery Doppler flow velocimetry in the prediction of preeclampsia, intrauterine growth retardation and perinatal death? An overview // Br. J. Obstet. Gynaecol. ‒ 2000. ‒ Vol. 107. ‒ P. 196‒208.Chien P.F., Arnott N., Gordon A. et al. How useful is uterine artery Doppler flow velocimetry in the prediction of preeclampsia, intrauterine growth retardation and perinatal death? An overview // Br. J. Obstet. Gynaecol. ‒ 2000. ‒ Vol. 107. ‒ P. 196‒208.Cnossen J.S., de Ruyter-Hanhijärvi H., van der Post J.A. et al. Accuracy of serum uric acid determination in predicting pre-eclampsia: a systematic review // Acta Obstet. Gynecol. Scand. ‒ 2006. ‒ Vol. 85, № 5. ‒ P. 519‒525.Cnossen J.S., de Ruyter-Hanhijärvi H., van der Post J.A. et al. Accuracy of serum uric acid determination in predicting pre-eclampsia: a systematic review // Acta Obstet. Gynecol. Scand. ‒ 2006. ‒ Vol. 85, № 5. ‒ P. 519‒525.Cnossen J.S., Vollebregt K.C., de Vrieze N. et al. Accuracy of mean arterial pressure and blood pressure measurements in predicting pre-eclampsia: systematic review and metaanalysis// Br. Med. J. ‒ 2008. ‒ Vol. 336. ‒ P. 1117‒1120.Cnossen J.S., Vollebregt K.C., de Vrieze N. et al. Accuracy of mean arterial pressure and blood pressure measurements in predicting pre-eclampsia: systematic review and metaanalysis// Br. Med. J. ‒ 2008. ‒ Vol. 336. ‒ P. 1117‒1120.Conde-Agudelo A., Romero R., Lindheimer M.D. Tests to predict preeclampsia in chesley’s hypertensive disorders in pregnancy. – 3-rd. ed. – New York: Academic Press, 2009. – P. 189‒211.Conde-Agudelo A., Romero R., Lindheimer M.D. Tests to predict preeclampsia in chesley’s hypertensive disorders in pregnancy. – 3-rd. ed. – New York: Academic Press, 2009. – P. 189‒211.Diesch C.H., Holzgreve W., Hahn S., Zhong X.Y. Comparison of activin A and cell-free fetal DNA levels in maternal plasma from patients at high risk for preeclampsia. Prenat Diagn 2006; 26: 1267—1270.Diesch C.H., Holzgreve W., Hahn S., Zhong X.Y. Comparison of activin A and cell-free fetal DNA levels in maternal plasma from patients at high risk for preeclampsia. Prenat Diagn 2006; 26: 1267—1270.Dugoff L., Hobbins J.C. et al. Quad screen as a predictor of adverse pregnancy outcome // Obstet. and Gynecol. ‒ 2005. ‒ Vol. 106, № 2. ‒ P. 260‒267.Dugoff L., Hobbins J.C. et al. Quad screen as a predictor of adverse pregnancy outcome // Obstet. and Gynecol. ‒ 2005. ‒ Vol. 106, № 2. ‒ P. 260‒267.Dugoff L., Hobbins J.C., Malone F.D. et al. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial) // Am. J. Obstet. Gynecol. – 2004. – Vol. 191. – P. 1446–1451.Dugoff L., Hobbins J.C., Malone F.D. et al. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial) // Am. J. Obstet. Gynecol. – 2004. – Vol. 191. – P. 1446–1451.Erez O., Romero R., Espinoza J. et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-forgestational age. J Matern Fetal Neonatal Med 2008; 21: 279—287Erez O., Romero R., Espinoza J. et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-forgestational age. J Matern Fetal Neonatal Med 2008; 21: 279—287Genest D.S., Falcao S., Gutkowska J., Lavoie J.L. Impact of exercise training on preeclampsia: potential preventive mechanisms. Hypertension. 2012; 60(5): 1104-9.Genest D.S., Falcao S., Gutkowska J., Lavoie J.L. Impact of exercise training on preeclampsia: potential preventive mechanisms. Hypertension. 2012; 60(5): 1104-9.Gonen R., Shahar R., Grimpel Y.I. et al. Placental protein 13 as an early marker for pre-eclampsia: a prospective longitudinal study // Br. J. Obstet. Gynaecol. – 2008. – Vol. 115. – P. 1465–1472.Gonen R., Shahar R., Grimpel Y.I. et al. Placental protein 13 as an early marker for pre-eclampsia: a prospective longitudinal study // Br. J. Obstet. Gynaecol. – 2008. – Vol. 115. – P. 1465–1472.Hansson S.R., Nääv Å., Erlandsson L. Oxidative stress in preeclampsia and the role of free fetal hemoglobin. Front. Physiol. 2015; 5: 516.Hansson S.R., Nääv Å., Erlandsson L. Oxidative stress in preeclampsia and the role of free fetal hemoglobin. Front. Physiol. 2015; 5: 516.Haram K., Svendsen E., Abildgaard U. The HELLP syndrome: clinical issues and management. A review. BMC Pregnancy Childbirth. 2009; 9: 8.Haram K., Svendsen E., Abildgaard U. The HELLP syndrome: clinical issues and management. A review. BMC Pregnancy Childbirth. 2009; 9: 8.Hunter A., Aitkenhead M., Caldwell C. et al. Serum levels of vascular endothelial growth factor in preeclamptic and normotensive pregnancy // Hypertension. ‒ 2000. ‒ Vol. 36, № 6. ‒ P. 965‒969.Hunter A., Aitkenhead M., Caldwell C. et al. Serum levels of vascular endothelial growth factor in preeclamptic and normotensive pregnancy // Hypertension. ‒ 2000. ‒ Vol. 36, № 6. ‒ P. 965‒969.Ives C.W., Sinkey R., Rajapreyar I., Tita A.T.N., Oparil S. Preeclampsia-pathophysiology and clinical presentations: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2020; 76(14): 1690-702. https://dx.doi.org/10.1016/j.jacc.2020.08.014.Ives C.W., Sinkey R., Rajapreyar I., Tita A.T.N., Oparil S. Preeclampsia-pathophysiology and clinical presentations: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2020; 76(14): 1690-702. https://dx.doi.org/10.1016/j.jacc.2020.08.014.Kang J.H., Farina A., Park J.H. et al. Down syndrome biochemical markers and screening for preeclampsia at first and second trimester: correlation with the week of onset and the severity // Prenat. Diagn. – 2008. – Vol. 28. – P. 704–709.Kang J.H., Farina A., Park J.H. et al. Down syndrome biochemical markers and screening for preeclampsia at first and second trimester: correlation with the week of onset and the severity // Prenat. Diagn. – 2008. – Vol. 28. – P. 704–709.Khong Y., Brosens I. Defective deep placentation. Best Pract. Res. Clin. Obstet. Gynaecol. 2010; 25(3): 301-11.Khong Y., Brosens I. Defective deep placentation. Best Pract. Res. Clin. Obstet. Gynaecol. 2010; 25(3): 301-11.Kyle P.M., Campbell S., Buckley D. et al. A comparison of the inactive urinary kallikrein: creatinine ratio and the angiotensin sensitivity test for the prediction of preeclampsia // Br. J. Obstet. Gynaecol. ‒ 1996. ‒ Vol. 103. ‒ P. 981–987.Kyle P.M., Campbell S., Buckley D. et al. A comparison of the inactive urinary kallikrein: creatinine ratio and the angiotensin sensitivity test for the prediction of preeclampsia // Br. J. Obstet. Gynaecol. ‒ 1996. ‒ Vol. 103. ‒ P. 981–987.Lam C., Lim K.H., Karumanchi S.A. et al. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia //Hypertension. ‒ 2005. ‒ Vol. 46. ‒ P. 1077–1085Lam C., Lim K.H., Karumanchi S.A. et al. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia //Hypertension. ‒ 2005. ‒ Vol. 46. ‒ P. 1077–1085Lara González A.L., Martínez Jaimes A., Romero Arauz J.F. et al. Microalbuminuria: early prognostic factor of preeclampsia? // Ginecol. Obstet. Mex. ‒ 2003. ‒ Vol. 71. ‒ P. 82–86.Lara González A.L., Martínez Jaimes A., Romero Arauz J.F. et al. Microalbuminuria: early prognostic factor of preeclampsia? // Ginecol. Obstet. Mex. ‒ 2003. ‒ Vol. 71. ‒ P. 82–86.Leeflang M.M., Cnossen J.S., van der Post J.A. et al. Accuracy of fibronectin tests for the prediction of pre-eclampsia: a systematic review // Eur. J. Obstet. Gynecol. Reprod. Biol. ‒ 2007. ‒ Vol. 133, № 1. ‒ P. 12–19.Leeflang M.M., Cnossen J.S., van der Post J.A. et al. Accuracy of fibronectin tests for the prediction of pre-eclampsia: a systematic review // Eur. J. Obstet. Gynecol. Reprod. Biol. ‒ 2007. ‒ Vol. 133, № 1. ‒ P. 12–19.Levine R.J., Qian C., LeShane E.S. et al. Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia. Am J Obstet Gynec 2004; 190: 707—713.Levine R.J., Qian C., LeShane E.S. et al. Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia. Am J Obstet Gynec 2004; 190: 707—713.Lisonkova S., Joseph K.S. Incidence of preeclampsia: risk factors and outcomes associated with early-versus late-onset disease. Am. J. Obstet. Gynecol. 2013; 209(6): 544. e1-544. e12.Lisonkova S., Joseph K.S. Incidence of preeclampsia: risk factors and outcomes associated with early-versus late-onset disease. Am. J. Obstet. Gynecol. 2013; 209(6): 544. e1-544. e12.Lo Y.M., Corbetta N., Chamberlain P.F. et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997; 350: 485—487.Lo Y.M., Corbetta N., Chamberlain P.F. et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997; 350: 485—487.Mayeur S., Lancel S., Theys N., Lukaszewski M.A., Duban-Deweer S., Bastide B. et al. Maternal calorie restriction modulates placental mitochondrial biogenesis and bioenergetic efficiency: putative involvement in fetoplacental growth defects in rats. Am. J. Physiol. Endocrinol. Metab. 2013; 304(1): Е14-22Mayeur S., Lancel S., Theys N., Lukaszewski M.A., Duban-Deweer S., Bastide B. et al. Maternal calorie restriction modulates placental mitochondrial biogenesis and bioenergetic efficiency: putative involvement in fetoplacental growth defects in rats. Am. J. Physiol. Endocrinol. Metab. 2013; 304(1): Е14-22Melamed N., Baschat A., Yinon Y., Athanasiadis A., Mecacci F., Figueras F. et al. FIGO (international Federation of Gynecology and Obstetrics) initiative on fetal growth: best practice advice for screening, diagnosis, and management of fetal growth restriction. Int. J. Gynaecol. Obstet. 2021; 152(Suppl. 1): 3-57.Melamed N., Baschat A., Yinon Y., Athanasiadis A., Mecacci F., Figueras F. et al. FIGO (international Federation of Gynecology and Obstetrics) initiative on fetal growth: best practice advice for screening, diagnosis, and management of fetal growth restriction. Int. J. Gynaecol. Obstet. 2021; 152(Suppl. 1): 3-57.Mignini L.E., Latthe P.M., Villar J. et al. Mapping the theories of preeclampsia: the role of homocysteine // Obstet. and Gynecol. ‒ 2005. ‒ Vol. 105. ‒ P. 411–425Mignini L.E., Latthe P.M., Villar J. et al. Mapping the theories of preeclampsia: the role of homocysteine // Obstet. and Gynecol. ‒ 2005. ‒ Vol. 105. ‒ P. 411–425Millar J.G., Campbell S.K., Albano J.D. et al. Early prediction of pre-eclampsia by measurement of kallikrein and creatinine on a random urine sample // Br. J. Obstet. Gynaecol. ‒ 1996. ‒ Vol. 103. ‒ P. 421‒426.Millar J.G., Campbell S.K., Albano J.D. et al. Early prediction of pre-eclampsia by measurement of kallikrein and creatinine on a random urine sample // Br. J. Obstet. Gynaecol. ‒ 1996. ‒ Vol. 103. ‒ P. 421‒426.NICE Clinical guideline CG107: Hypertension in Pregnancy: the management of hypertensive disorders during pregnancy. Surveillance proposal GE document, 2015. 71 p. Available at: https://www.nice.org.uk/guidance/cg107/resources/cg107-hypertension-in-pregnancy-surveillance-review-decision-march-20153NICE Clinical guideline CG107: Hypertension in Pregnancy: the management of hypertensive disorders during pregnancy. Surveillance proposal GE document, 2015. 71 p. Available at: https://www.nice.org.uk/guidance/cg107/resources/cg107-hypertension-in-pregnancy-surveillance-review-decision-march-20153Opichka M.A., Rappelt M.W., Gutterman D.D., Grobe J.L., McIntosh J.J. Review vascular dysfunction in preeclampsia. Cells. 2021; 10(11): 3055.Opichka M.A., Rappelt M.W., Gutterman D.D., Grobe J.L., McIntosh J.J. Review vascular dysfunction in preeclampsia. Cells. 2021; 10(11): 3055.Parra-Cordero M., Turan O.M., Kaur A. et al. Maternal serum soluble adhesion molecule levels at 11+0-13+6 weeks and subsequent development of pre-eclampsia // J. Matern. Fetal Neonatal Med. ‒ 2007. – Vol. 20. – P. 793–796.Parra-Cordero M., Turan O.M., Kaur A. et al. Maternal serum soluble adhesion molecule levels at 11+0-13+6 weeks and subsequent development of pre-eclampsia // J. Matern. Fetal Neonatal Med. ‒ 2007. – Vol. 20. – P. 793–796.Poston L., Igosheva N., Mistry H.D., Seed P.T., Shennan A.H., Rana S. et al. Role of oxidative stress and antioxidant supplementation in pregnancy disorders. Am. J. Clin. Nutr. 2011; 94(6, Suppl.): 1980S-5S.Poston L., Igosheva N., Mistry H.D., Seed P.T., Shennan A.H., Rana S. et al. Role of oxidative stress and antioxidant supplementation in pregnancy disorders. Am. J. Clin. Nutr. 2011; 94(6, Suppl.): 1980S-5S.Rana S., Karumanchi S.A., Levine R.J. et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing pr eeclampsia. Hypertension 2007; 50: 137—142.Rana S., Karumanchi S.A., Levine R.J. et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing pr eeclampsia. Hypertension 2007; 50: 137—142.Roberts J.M., Pearson G., Cutler J. et al. Summary of the NHLBI working group on research on hypertension during pregnancy // Hypertension. ‒ 2003. ‒ Vol. 41. ‒ P. 437‒445.Roberts J.M., Pearson G., Cutler J. et al. Summary of the NHLBI working group on research on hypertension during pregnancy // Hypertension. ‒ 2003. ‒ Vol. 41. ‒ P. 437‒445.Rodie V.A., Freeman D.J., Sattar N. et al. Pre-eclampsia and cardiovascular disease: metabolic syndrome of pregnancy // Atherosclerosis. ‒ 2004. ‒ Vol. 175, № 2. ‒ P. 189‒202Rodie V.A., Freeman D.J., Sattar N. et al. Pre-eclampsia and cardiovascular disease: metabolic syndrome of pregnancy // Atherosclerosis. ‒ 2004. ‒ Vol. 175, № 2. ‒ P. 189‒202Romero R., Kusanovic J.P., Than N.G. et al. First-trimester maternal serum PP13 in the risk assessment for preeclampsia // Am. J. Obstet. Gynecol. – 2008. – Vol. 199. – P. 122. e1–122.e11.Romero R., Kusanovic J.P., Than N.G. et al. First-trimester maternal serum PP13 in the risk assessment for preeclampsia // Am. J. Obstet. Gynecol. – 2008. – Vol. 199. – P. 122. e1–122.e11.Sayin N.C., Canda M.T., Ahmet N. et al. The association of triple-marker test results with adverse pregnancy outcomes in low-risk pregnancies with healthy newborns // Arch. Gynecol. Obstet. – 2008. – Vol. 277. – P. 47–53.Sayin N.C., Canda M.T., Ahmet N. et al. The association of triple-marker test results with adverse pregnancy outcomes in low-risk pregnancies with healthy newborns // Arch. Gynecol. Obstet. – 2008. – Vol. 277. – P. 47–53.Shaarawy M., Salem M.E. The clinical value of microtransferrinuria and microalbuminuria in the prediction of preeclampsia // Clin. Chem. Lab. Med. – 2001. – Vol. 39, № 1. – P. 29‒34.Shaarawy M., Salem M.E. The clinical value of microtransferrinuria and microalbuminuria in the prediction of preeclampsia // Clin. Chem. Lab. Med. – 2001. – Vol. 39, № 1. – P. 29‒34.Spencer K., Yu C.K.H., Cowans N.J. et al. Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free hCG and with second-trimester uterine artery Doppler // Prenat. Diagn. – 2005. – Vol. 25. – P. 949–953Spencer K., Yu C.K.H., Cowans N.J. et al. Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free hCG and with second-trimester uterine artery Doppler // Prenat. Diagn. – 2005. – Vol. 25. – P. 949–953

The authors declare that there are no conflicts of interest present.